{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:13:59Z","timestamp":1762521239295,"version":"build-2065373602"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.3816\/cbc.2008.n.012","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:05:35Z","timestamp":1221080735000},"page":"124-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Low-Dose Estrogen Therapy to Reverse Acquired Antihormonal Resistance in the Treatment of Breast Cancer"],"prefix":"10.3816","volume":"8","author":[{"given":"Ramona F.","family":"Swaby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2008.n.012_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.AOG.0000220502.77153.5a","article-title":"Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003","volume":"108","author":"Hing","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.3816\/CBC.2008.n.012_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.gme.0000229571.44505.cb","article-title":"Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists","volume":"14","author":"Power","year":"2007","journal-title":"Menopause"},{"key":"10.3816\/CBC.2008.n.012_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breastcancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases","volume":"11","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.012_bib5","first-page":"1161","article-title":"On oophorectomy in cancer of the breast","volume":"2","author":"Boyd","year":"1900","journal-title":"Br Med J"},{"key":"10.3816\/CBC.2008.n.012_bib6","first-page":"3071","article-title":"MCF-7: the first hormone-responsive breast cancer cell line","volume":"57","author":"Levenson","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib7","first-page":"5183","article-title":"Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib8","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-05-2584","article-title":"Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice","volume":"12","author":"O'Regan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/oxfordjournals.annonc.a058286","article-title":"Response after withdrawal of tamoxifen and progestogens in advanced breast cancer","volume":"3","author":"Howell","year":"1992","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2008.n.012_bib11","first-page":"19","article-title":"Deaths: final data for 2004","volume":"55","author":"Minino","year":"2007","journal-title":"National vital statistics reports, CDC"},{"key":"10.3816\/CBC.2008.n.012_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.3816\/CBC.2008.n.012_bib14","first-page":"419","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study [published erratum in: Lancet 2003; 362:1160]","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.012_bib15","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"key":"10.3816\/CBC.2008.n.012_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/141247b0","article-title":"Oestrogenic activity of certain synthetic compounds","volume":"141","author":"Dodds","year":"1938","journal-title":"Nature"},{"key":"10.3816\/CBC.2008.n.012_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/142292a0","article-title":"Duration of action of natural and synthetic estrogens","volume":"142","author":"Robson","year":"1938","journal-title":"Nature"},{"key":"10.3816\/CBC.2008.n.012_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J Endocrinol"},{"key":"10.3816\/CBC.2008.n.012_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1980.tb10912.x","article-title":"Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships","volume":"71","author":"Allen","year":"1980","journal-title":"Br J Pharmacol"},{"key":"10.3816\/CBC.2008.n.012_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000226637","article-title":"Phase II evaluation of Ly156758 in metastatic breast cancer","volume":"45","author":"Buzdar","year":"1988","journal-title":"Oncology"},{"key":"10.3816\/CBC.2008.n.012_bib21","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [published erratum in: JAMA 1999; 282:2124]","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.3816\/CBC.2008.n.012_bib22","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published errata in: JAMA 2006; 296:2926 and JAMA 2007; 298:973]","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.3816\/CBC.2008.n.012_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Eng J Med"},{"key":"10.3816\/CBC.2008.n.012_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bmj.2.4368.393","article-title":"Influence of synthetic oestrogens upon advanced malignant disease","volume":"2","author":"Haddow","year":"1944","journal-title":"Br Med J"},{"key":"10.3816\/CBC.2008.n.012_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1056\/NEJM197108122850707","article-title":"Vaginal cancer after maternal treatment with synthetic estrogens","volume":"285","author":"Greenwald","year":"1971","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM197104222841604","article-title":"Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women","volume":"284","author":"Herbst","year":"1971","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib27","first-page":"4177","article-title":"Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture","volume":"50","author":"Lerner","year":"1990","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1095\/biolreprod25.3.667","article-title":"Agonistic and antagonistic effects of clomiphene citrate and its isomer","volume":"25","author":"Clark","year":"1981","journal-title":"Biol Reprod"},{"key":"10.3816\/CBC.2008.n.012_bib29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/0002-9378(62)90067-4","article-title":"Induction of ovulation","volume":"84","author":"Greenblatt","year":"1962","journal-title":"Am J Obstet Gynecol"},{"key":"10.3816\/CBC.2008.n.012_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/jrf.0.0130101","article-title":"A new derivative of triphenylethylene: effect on implantation and mode of action in rats","volume":"13","author":"Harper","year":"1967","journal-title":"J Reprod Fertil"},{"key":"10.3816\/CBC.2008.n.012_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.3816\/CBC.2008.n.012_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous estrogen and endometrial carcinoma","volume":"293","author":"Smith","year":"1975","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","article-title":"Increased risk of endometrial carcinoma among users of conjugated estrogens","volume":"293","author":"Ziel","year":"1975","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib34","first-page":"1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause [published erratum in: JAMA 2008; 299:1426]","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.3816\/CBC.2008.n.012_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2125.2005.02502.x","article-title":"Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study","volume":"60","author":"Faber","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CBC.2008.n.012_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.maturitas.2005.10.010","article-title":"HRT use in 2001 and 2004 in The Netherlands\u2013a world of difference","volume":"54","author":"de Jong-van den Berg","year":"2006","journal-title":"Maturitas"},{"key":"10.3816\/CBC.2008.n.012_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00228-005-0083-x","article-title":"Effect of clinical trial publicity on HRT prescribing in Ireland","volume":"62","author":"Usher","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3816\/CBC.2008.n.012_bib38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/1097-0142(196512)18:12<1551::AID-CNCR2820181206>3.0.CO;2-1","article-title":"Hormone therapy for advanced breast cancer","volume":"18","author":"Kennedy","year":"1965","journal-title":"Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib39","first-page":"387","article-title":"Basic guides to the mechanism of estrogen action","volume":"18","author":"Jensen","year":"1962","journal-title":"Recent Progr Horm Res"},{"key":"10.3816\/CBC.2008.n.012_bib40","first-page":"55","article-title":"Estrogen receptors and breast cancer response to adrenalectomy","volume":"34","author":"Jensen","year":"1971","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.3816\/CBC.2008.n.012_bib41","series-title":"Estrogen Receptor in Human Breast Cancer","first-page":"1","article-title":"Estrogen receptors in human breast cancer: an overview","author":"McGuire","year":"1975"},{"key":"10.3816\/CBC.2008.n.012_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.1.5741.152","article-title":"New synthetic agent for the induction of ovulation: preliminary trials in women","volume":"1","author":"Klopper","year":"1971","journal-title":"Br Med J"},{"key":"10.3816\/CBC.2008.n.012_bib43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/joe.0.0680297","article-title":"Tamoxifen as an anti-tumour agent: effect on oestrogen binding","volume":"68","author":"Jordan","year":"1976","journal-title":"J Endocrinol"},{"key":"10.3816\/CBC.2008.n.012_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.0680453","article-title":"Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response","volume":"68","author":"Jordan","year":"1976","journal-title":"J Endocrinol"},{"key":"10.3816\/CBC.2008.n.012_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","article-title":"Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata","volume":"12","author":"Jordan","year":"1976","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2964(75)90119-X","article-title":"Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor","volume":"11","author":"Jordan","year":"1975","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.steroids.2006.10.009","article-title":"Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer","volume":"72","author":"Jordan","year":"2007","journal-title":"Steroids"},{"key":"10.3816\/CBC.2008.n.012_bib49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0140-6736(84)92795-8","article-title":"4-hydroxyandostenedione in treatment of postmenopausal patients with advanced breast cancer","volume":"2","author":"Coombes","year":"1984","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.012_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/212087a0","article-title":"Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes","volume":"212","author":"Harper","year":"1966","journal-title":"Nature"},{"key":"10.3816\/CBC.2008.n.012_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.1.5844.13","article-title":"Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels","volume":"1","author":"Ward","year":"1973","journal-title":"Br Med J"},{"key":"10.3816\/CBC.2008.n.012_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM198101013040104","article-title":"Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer","volume":"304","author":"Ingle","year":"1981","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.3816\/CBC.2008.n.012_bib53","first-page":"83","article-title":"The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer","author":"Stewart","year":"1980","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib54","first-page":"179","article-title":"Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer","volume":"65","author":"Beex","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.3816\/CBC.2008.n.012_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00000421-198504000-00004","article-title":"Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer","volume":"8","author":"Matelski","year":"1985","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CBC.2008.n.012_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1006185805079","article-title":"Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis","volume":"54","author":"Peethambaram","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2008.n.012_bib57","first-page":"19","article-title":"The effectiveness of long-term treatment in a laboratory model for adjuvant hormone therapy of breast cancer","volume":"2","author":"Jordan","year":"1979"},{"key":"10.3816\/CBC.2008.n.012_bib58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBAinduced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib59","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.012_bib60","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.012_bib61","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Nat Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib62","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Nat Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib63","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer [published erratum in: J Nat Cancer Inst 2000; 92:375]","volume":"91","author":"Gail","year":"1999","journal-title":"J Nat Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.012_bib65","first-page":"2747","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published erratum in: N Engl J Med 2006; 354:2200]","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib66","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [published errata in: N Eng J Med 2004; 351:2461 and N Eng J Med 2006; 355:1746]","volume":"350","author":"Coombes","year":"2004","journal-title":"N Eng J Med"},{"key":"10.3816\/CBC.2008.n.012_bib67","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2008.n.012_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2008.n.012_bib69","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model","volume":"47","author":"Gottardis","year":"1987","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib70","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/07357908809082124","article-title":"Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations","volume":"6","author":"Jordan","year":"1988","journal-title":"Cancer Invest"},{"key":"10.3816\/CBC.2008.n.012_bib71","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.3816\/CBC.2008.n.012_bib72","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib73","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.ejca.2006.09.012","article-title":"Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial","volume":"42","author":"Jordan","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib74","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib75","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.012_bib76","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib77","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2008.n.012_bib78","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2008.n.012_bib79","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1096\/fj.06-7990com","article-title":"Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines","volume":"21","author":"Gomez","year":"2007","journal-title":"FASEB J"},{"key":"10.3816\/CBC.2008.n.012_bib80","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jnci\/djg079","article-title":"Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer","volume":"95","author":"Osipo","year":"2003","journal-title":"J Nat Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib81","series-title":"Recent Results in Cancer Research","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-3-642-84745-5_4","article-title":"A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy","author":"Wolf","year":"1993"},{"key":"10.3816\/CBC.2008.n.012_bib82","first-page":"2028","article-title":"Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Yao","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib83","first-page":"509","article-title":"Role for HER2\/neu and HER3 in fulvestrant-resistant breast cancer","volume":"30","author":"Osipo","year":"2007","journal-title":"Int J Oncol"},{"key":"10.3816\/CBC.2008.n.012_bib84","first-page":"4355","article-title":"Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens","volume":"47","author":"Katzenellenbogen","year":"1987","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib85","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/0277-5379(87)90062-9","article-title":"Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture","volume":"232","author":"Welshons","year":"1987","journal-title":"European J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0303-7207(92)90104-E","article-title":"An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol","volume":"90","author":"Jiang","year":"1992","journal-title":"Mol and Cell Endo"},{"key":"10.3816\/CBC.2008.n.012_bib87","first-page":"2583","article-title":"An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein","volume":"55","author":"Pink","year":"1995","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2008.n.012_bib88","first-page":"2918","article-title":"Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells","volume":"80","author":"Masamura","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CBC.2008.n.012_bib89","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/jnci\/93.22.1714","article-title":"Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17betaestradiol","volume":"93","author":"Song","year":"2001","journal-title":"J Nat Cancer Inst"},{"key":"10.3816\/CBC.2008.n.012_bib90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jsbmb.2004.12.032","article-title":"Estrogen induced apoptosis in breast cancer model resistant to long-term estrogen withdrawal","volume":"94","author":"Lewis","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.3816\/CBC.2008.n.012_bib91","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/jnci\/dji400","article-title":"Intrinsic mechanism of estradiolinduced apoptosis in breast cancer cells resistant to estrogen deprivation","volume":"97","author":"Lewis","year":"2005","journal-title":"JNCI"},{"key":"10.3816\/CBC.2008.n.012_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1021649019025","article-title":"Apoptotic action of estrogen","volume":"8","author":"Song","year":"2003","journal-title":"Apoptosis"},{"issue":"suppl 2","key":"10.3816\/CBC.2008.n.012_bib93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.breast.2007.07.020","article-title":"Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients","volume":"16","author":"Jordan","year":"2007","journal-title":"Breast"},{"issue":"suppl 1","key":"10.3816\/CBC.2008.n.012_bib94","first-page":"107","article-title":"Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women","author":"Mouridsen","year":"1980","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2008.n.012_bib95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"Lonning","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2008.n.012_bib96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: concept and consequences in cancer","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911704980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911704980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:14Z","timestamp":1761512954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911704980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1526820911704980"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2008.n.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Estrogen Therapy to Reverse Acquired Antihormonal Resistance in the Treatment of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2008.n.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}